Increased expression of CD81 is associated with poor prognosis of prostate cancer and increases the progression of prostate cancer cells in�vitro

Qian, Haining; Xu, Antao; Yang, Gang

doi:10.3892/etm.2019.8244

Cited by 11 publications

(16 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD81, one of the most studied tetraspanins, has been especially associated with malignant cellular transformation (27). It has been shown that down-regulation of CD81 in several cancers is associated with reduced tumor growth, migration, and cell invasion (8,28,29), and overexpression of CD81 in melanoma, increases metastasis (7). Here, we knocked out CD81 in a triple-negative mouse breast cancer, which resulted in reduced tumor growth and less metastasis, confirming the importance of CD81 during cancer progression.…”

Section: Discussionmentioning

confidence: 99%

Targeting the tetraspanin CD81 reduces cancer invasion and metastasis

Vences-Catalán

Rajapaksa

Kuo

et al. 2021

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Tetraspanins are an evolutionary conserved family of proteins involved in multiple aspects of cell physiology, including proliferation, migration and invasion, protein trafficking, and signal transduction; yet their detailed mechanism of action is unknown. Tetraspanins have no known natural ligands, but their engagement by antibodies has begun to reveal their role in cell biology. Studies of tetraspanin knockout mice and of germline mutations in humans have highlighted their role under normal and pathological conditions. Previously, we have shown that mice deficient in the tetraspanin CD81 developed fewer breast cancer metastases compared to their wild-type (WT) counterparts. Here, we show that a unique anti-human CD81 antibody (5A6) effectively halts invasion of triple-negative breast cancer (TNBC) cell lines. We demonstrate that 5A6 induces CD81 clustering at the cell membrane and we implicate JAM-A protein in the ability of this antibody to inhibit tumor cell invasion and migration. Furthermore, in a series of in vivo studies we demonstrate that this antibody inhibits metastases in xenograft models, as well as in syngeneic mice bearing a mouse tumor into which we knocked in the human CD81 epitope recognized by the 5A6 antibody.

show abstract

Section: Discussionmentioning

confidence: 99%

Targeting the tetraspanin CD81 reduces cancer invasion and metastasis

Vences-Catalán

Rajapaksa

Kuo

et al. 2021

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…Intriguingly, the suppression of some of the identified immune response genes, including CD81, might contribute to the suppression of cancer cells migration and invasive capacity ( 29 ). Moreover, treatment with GN25 is suppressing BCL6 which was shown to alternatively promote cancer cells survival through exerting a suppressive effect on DNA damage sensing proteins including p53 ( 30 ).…”

Section: Resultsmentioning

confidence: 99%

Systems Immunology Analysis Reveals an Immunomodulatory Effect of Snail-p53 Binding on Neutrophil- and T Cell-Mediated Immunity in KRAS Mutant Non-Small Cell Lung Cancer

et al. 2020

View full text Add to dashboard Cite

Immunomodulation and chronic inflammation are important mechanisms utilized by cancer cells to evade the immune defense and promote tumor progression. Therefore, various efforts were focused on the development of approaches to reprogram the immune response to increase the immune detection of cancer cells and enhance patient response to various types of therapy. A number of regulatory proteins were investigated and proposed as potential targets for immunomodulatory therapeutic approaches including p53 and Snail. In this study, we investigated the immunomodulatory effect of disrupting Snail-p53 binding induced by the oncogenic KRAS to suppress p53 signaling. We analyzed the transcriptomic profile mediated by Snail-p53 binding inhibitor GN25 in non-small cell lung cancer cells (A549) using Next generation whole RNA-sequencing. Notably, we observed a significant enrichment in transcripts involved in immune response pathways especially those contributing to neutrophil (IL8) and T-cell mediated immunity (BCL6, and CD81). Moreover, transcripts associated with NF-κB signaling were also enriched which may play an important role in the immunomodulatory effect of Snail-p53 binding. Further analysis revealed that the immune expression signature of GN25 overlaps with the signature of other therapeutic compounds known to exhibit immunomodulatory effects validating the immunomodulatory potential of targeting Snail-p53 binding. The effects of GN25 on the immune response pathways suggest that targeting Snail-p53 binding might be a potentially effective therapeutic strategy.

show abstract

“…An in vitro experiment by Wu et al (52) proved that CENPN expression levels were positively associated with the WHO grade of glioma and that CENPN promoted malignant glioma cell phenotypes. Although OGFOD1, C1RL, CD81, and ITPKC play pivotal roles in several cancers, their involvement in glioblastoma remains undocumented (53)(54)(55)(56).…”

Section: Discussionmentioning

confidence: 99%

Development of a Novel Prognostic Model of Glioblastoma Based on m6A-Associated Immune Genes and Identification of a New Biomarker

Luo

Sun

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundAccumulating evidence shows that m6A regulates oncogene and tumor suppressor gene expression, thus playing a dual role in cancer. Likewise, there is a close relationship between the immune system and tumor development and progression. However, for glioblastoma, m6A-associated immunological markers remain to be identified.MethodsWe obtained gene expression, mutation, and clinical data on glioblastoma from The Cancer Genome Atlas and Chinese Glioma Genome Atlas databases. Next, we performed univariate COX–least absolute shrinkage and selection operator (LASSO)–multivariate COX regression analyses to establish a prognostic gene signature and develop a corresponding dynamic nomogram application. We then carried out a clustering analysis twice to categorize all samples according to their m6A-regulating and m6A-associated immune gene expression levels (high, medium, and low) and calculated their m6A score. Finally, we performed quantitative reverse transcription-polymerase chain reaction, cell counting kit-8, cell stemness detection, cell migration, and apoptosis detection in vitro assays to determine the biological role of CD81 in glioblastoma cells.ResultsOur glioblastoma risk score model had extremely high prediction efficacy, with the area under the receiver operating characteristic curve reaching 0.9. The web version of the dynamic nomogram application allows rapid and accurate calculation of patients’ survival odds. Survival curves and Sankey diagrams indicated that the high-m6A score group corresponded to the groups expressing medium and low m6A-regulating gene levels and high m6A-associated prognostic immune gene levels. Moreover, these groups displayed lower survival rates and higher immune infiltration. Based on the gene set enrichment analysis, the pathophysiological mechanism may be related to the activation of the immunosuppressive function and related signaling pathways. Moreover, the risk score model allowed us to perform immunotherapy benefit assessment. Finally, silencing CD81 in vitro significantly suppressed proliferation, stemness, and migration and facilitated apoptosis in glioblastoma cells.ConclusionWe developed an accurate and efficient prognostic model. Furthermore, the correlation analysis of different stratification methods with tumor microenvironment provided a basis for further pathophysiological mechanism exploration. Finally, CD81 may serve as a diagnostic and prognostic biomarker in glioblastoma.

show abstract

Increased expression of CD81 is associated with poor prognosis of prostate cancer and increases the progression of prostate cancer cells in�vitro

Cited by 11 publications

References 35 publications

Targeting the tetraspanin CD81 reduces cancer invasion and metastasis

Targeting the tetraspanin CD81 reduces cancer invasion and metastasis

Systems Immunology Analysis Reveals an Immunomodulatory Effect of Snail-p53 Binding on Neutrophil- and T Cell-Mediated Immunity in KRAS Mutant Non-Small Cell Lung Cancer

Development of a Novel Prognostic Model of Glioblastoma Based on m6A-Associated Immune Genes and Identification of a New Biomarker

Contact Info

Product

Resources

About